When researchers at the Endocrine Society's ENDO 2026 annual meeting reported June 16–17, 2026, that prenatal and early postnatal exposure to DEHP causes lasting anxiety-like behavioral changes in male rats — changes that persist into adulthood even after exposure has completely ended — they identified a specific biological window of vulnerability with an exact real-world analog that demands immediate clinical attention.
That analog is the neonatal intensive care unit.
According to the Endocrine Society's press release and ScienceDaily's coverage, lead researcher Osvaldo Juan Ponzo, M.D., Ph.D., of the University of Buenos Aires, identified the prenatal and immediate postnatal developmental period as the critical window for DEHP's neurological effects. This is precisely the developmental window during which premature infants spend weeks or months in NICUs — connected to polyvinyl chloride (PVC) tubing, IV lines, ventilator circuits, nasogastric feeding tubes, and oxygen delivery equipment. Virtually all standard NICU tubing and equipment are made from PVC. Most PVC medical equipment is plasticized with DEHP.
Why NICU Infants Are the Most DEHP-Exposed Humans in the World
The degree of DEHP exposure in NICU infants is not a marginal concern. It is documented, quantified, and substantial, and it occurs at the most neurologically sensitive point in a human life.
DEHP leaches continuously from PVC tubing into intravenous fluids, blood products, lipid emulsions, and medications as they pass through the tubing. The leaching rate increases with fat content (lipid emulsions leach more), temperature (body temperature accelerates leaching), and contact time (more hours of infusion = more total DEHP delivered). For a premature infant connected to multiple infusion lines, ventilator circuits, and feeding tubes around the clock for weeks — at a developmental stage when the blood-brain barrier is not yet fully formed, and the brain is undergoing its most rapid growth and neural circuit formation — the cumulative DEHP exposure is substantially higher, per unit of body weight, than virtually any other human exposure scenario.
Studies have measured urinary phthalate metabolite levels in NICU infants and found them to be dramatically elevated compared to infants not in intensive care. A 2016 study in JAMA Pediatrics found that infants admitted to the NICU had DEHP metabolite levels approximately 6 to 14 times higher than typical infant levels, depending on the procedures and equipment involved. Research published in Environmental Health Perspectives found a dose-response relationship between days in the NICU and DEHP metabolite levels.
This exposure profile is significant in the context of the ENDO 2026 findings because the developmental window studied in the rats — prenatal and immediate postnatal — corresponds to approximately 24 to 40 weeks of gestational age in humans: precisely the window in which premature infants are in NICUs. The critical period for DEHP's effects on testosterone-dependent brain circuit development coincides exactly with the period of NICU care for the smallest and most vulnerable premature infants.
| DEHP in NICUs — Key Data | Detail |
| Primary DEHP source in NICUs | PVC tubing, IV bags, ventilator circuits, NG tubes, oxygen equipment |
| DEHP leaching mechanism | Plasticizer migrates into fluids passing through PVC tubing |
| Factors increasing leaching | Fat content, temperature, contact time |
| NICU infant DEHP exposure (vs. typical infants) | 6–14x higher urinary DEHP metabolites (JAMA Pediatrics 2016) |
| Most vulnerable developmental window for DEHP effects | Prenatal and immediate postnatal (per ENDO 2026 study) |
| NICU care window for premature infants | Approximately 24–40 weeks gestational age |
| Overlap of vulnerability window and NICU window | Direct — the critical period and the NICU period coincide |
| EU regulatory response | 2023 deadline restricting DEHP in medical devices |
| U.S. FDA regulatory response | Acknowledged risk (2002, 2008 Safety Assessment reports); no mandatory restriction on medical DEHP |
| Non-DEHP PVC alternatives available | Yes — DEHP-free medical tubing exists; adoption in U.S. NICUs is not universal |
The Regulatory Gap — Europe Acted, the U.S. Has Not
The risk of DEHP in medical devices is not new to regulators. In 2002, the FDA published a safety assessment concluding that male fetuses and neonates were at the highest risk from DEHP in medical devices. In 2008, the FDA published a follow-up safety assessment that again acknowledged the concern, while stopping short of mandatory restrictions. The FDA's current guidance is voluntary and advisory, recommending that hospitals consider using DEHP-free alternatives for neonates, male infants, pregnant women, and peripubertal males when alternatives are available.
The European Union took a stronger step. In 2023, the EU Commission implemented mandatory restrictions on DEHP in medical devices for direct patient contact, requiring DEHP-free alternatives or specific risk justifications for continued use. EU hospitals have been actively transitioning NICU equipment toward DEHP-free alternatives.
MedicalXpress reporting on the ENDO 2026 findings noted the significance of DEHP's presence in medical equipment: "DEHP is used in many plastic items to make them more flexible, such as medical devices, toys, shower curtains and raincoats." The medical device category is the most acute concern because it is where the most intensive exposure of the most vulnerable population occurs.
In U.S. NICUs, DEHP-free tubing and equipment are available from multiple manufacturers. Adoption varies by institution. Some children's hospitals have moved toward DEHP-free NICU protocols; many community hospitals have not. No federal mandate currently requires DEHP-free equipment in U.S. NICUs.
What Clinicians, Parents, and Hospitals Can Do
For NICU clinicians and hospital administrators, the ENDO 2026 data — combined with the existing body of evidence on DEHP's endocrine-disrupting effects in the most vulnerable developmental window — strengthens the case for institutional protocols requiring DEHP-free medical equipment for premature and newborn infants.
DEHP-free alternatives for common NICU equipment are commercially available:
- DEHP-free IV tubing : Multiple manufacturers produce PVC tubing plasticized with DINP (diisononyl phthalate), TOTM (tris(2-ethylhexyl) trimellitate), or non-phthalate plasticizers
- DEHP-free blood and lipid administration sets : Critical, given that lipid emulsions dramatically accelerate DEHP leaching
- DEHP-free respiratory circuits and NG tubes
For parents of premature infants currently in NICU care, the appropriate first step is to ask the neonatal care team about the institution's policy on DEHP-free medical equipment — specifically for IV tubing, blood products, and lipid infusions, where DEHP leaching is highest. Parents have the right to ask what materials are in contact with their child and to request DEHP-free alternatives if the institution has them available.
The ENDO 2026 data does not establish that DEHP causes anxiety disorders in preterm human infants. The study was conducted in rats. But the animal-to-human risk signal is consistent with prior epidemiological studies linking maternal phthalate exposure during pregnancy to behavioral outcomes in children, and the developmental biology of the critical window identified is directly applicable to preterm NICU populations. The convergence of laboratory evidence, epidemiological data, a precisely identified vulnerable developmental window, and documented high NICU exposure creates an evidence base that regulatory experts and neonatologists say warrants a stronger precautionary response than the U.S. has implemented.
Frequently Asked Questions
Why are NICU infants so heavily exposed to DEHP?
Standard NICU medical tubing, IV bags, ventilator circuits, and feeding equipment are made from PVC plasticized with DEHP. DEHP leaches continuously from PVC tubing into fluids, especially fat-containing lipid emulsions. Premature infants connected to these devices around the clock for weeks accumulate DEHP exposure that is 6–14 times higher per unit body weight than typical infant levels.
Why does the ENDO 2026 study matter for NICU infants specifically?
The study identified the prenatal and immediate postnatal developmental period as the critical window for DEHP's neurological effects on anxiety. This window — approximately 24–40 weeks gestational age — corresponds exactly to the period during which premature infants receive NICU care. The most vulnerable developmental period and the period of highest medical DEHP exposure coincide directly.
What has the FDA done about DEHP in medical devices?
The FDA published safety assessments in 2002 and 2008, acknowledging that neonates and male fetuses are at the highest risk from DEHP in medical devices. The current FDA guidance is voluntary, recommending that hospitals consider DEHP-free alternatives for neonates when available. No mandatory restrictions have been imposed.
What did the EU do differently?
The European Commission implemented mandatory restrictions on DEHP in medical devices for direct patient contact in 2023, requiring DEHP-free alternatives or specific risk justifications for continued DEHP use. EU hospitals are actively transitioning NICU equipment accordingly.
What can parents ask about in the NICU?
Ask the care team whether the IV tubing, blood product sets, lipid infusion lines, and ventilator circuits used for your infant are DEHP-free. DEHP-free alternatives exist for all of these products. If the institution has DEHP-free options available, parents can request they be used for their infant's care.
